The expansion arrives as healthcare systems prioritize supply chain resilience and the diversification of biologic medicine sources. By bolstering its industrial platform, the firm aims to ensure the continuity of treatment for patients managing rare and chronic conditions. This infrastructure investment allows Biosidus to engage with health authorities and potential partners seeking reliable access to high-quality therapeutic alternatives.
Following the domestic launch of its agalsidase beta therapy in 2025, the company is now positioning its program for cross-border distribution. Mario Koch, Director of Rare Diseases, emphasized that the added capacity serves the company’s broader objective of making complex biologics more accessible globally. Biosidus is currently prepared to evaluate supply requirements in markets where regulatory pathways support the introduction of new biosimilar options.
Comments (0)
No comments yet. Be the first!